AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1985173 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Hydroperoxycyclophosphamide (4-HC) at 60 micrograms/mL
Number of subjects: 25
Study 1985173 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Hydroperoxycyclophosphamide (4-HC) at 80 micrograms/mL
Number of subjects: 25
Study 1985173 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment program
Number of subjects: 25
Study 97718 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 97718 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 31915040 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of tetracosactide intravenously over 20 min
Number of subjects: 0
Study 31915040 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 0
Study 30637882 — intervention group
Group type: COMPARATOR
Intervention: Fazekas 3 group
Number of subjects: 1454
Study 28655802 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text messages containing simple medical facts or quiz questions
Number of subjects: 70
Study 26340453 — intervention group
Group type: EXPERIMENTAL
Intervention: hf-TENS/thermotherapy device
Number of subjects: 115
Study 26340453 — intervention group
Group type: COMPARATOR
Intervention: sham device
Number of subjects: 115
Study 23892860 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials provided to physicians
Number of subjects: 91
Study 21287410 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol treatment group
Number of subjects: 340
Study 21287410 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment group
Number of subjects: 340
Study 19933935 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum long-chain n-3 polyunsaturated fatty acids (PUFAs) - specifically eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid
Number of subjects: 2174
Study 19933935 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum docosahexaenoic acid
Number of subjects: 2174
Study 19933935 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion of subjects with myocardial infarction or congestive heart failure
Number of subjects: 2174
Study 19933935 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum intermediate chain-length n-3 PUFA, alpha-linolenic acid, or hair methylmercury concentration
Number of subjects: 2174
Study 17301072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored FEC (5-fluorouracil, epirubicin, cyclophosphamide)
Number of subjects: 525
Study 17301072 — intervention group
Group type: COMPARATOR
Intervention: CTCb (cyclophosphamide, thiotepa, carboplatin)
Number of subjects: 525
Study 17301072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored FEC
Number of subjects: 525
Study 17301072 — intervention group
Group type: COMPARATOR
Intervention: CTCb
Number of subjects: 525
Study 16614584 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation protocol
Number of subjects: 27
Study 16614584 — intervention group
Group type: COMPARATOR
Intervention: Low anesthetic dose
Number of subjects: 27
Study 16614584 — intervention group
Group type: COMPARATOR
Intervention: Normothermic temperature management
Number of subjects: 27
Study 16614584 — intervention group
Group type: COMPARATOR
Intervention: Fast-track treatment
Number of subjects: 27
Study 12795460 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS patients
Number of subjects: 51
Study 12795460 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS non-patients
Number of subjects: 51
Study 12795460 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 51
Study 10215471 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D fast asymmetric spin echo (FASE) imaging
Number of subjects: 0
Study 10215471 — intervention group
Group type: COMPARATOR
Intervention: 3D fast spin echo (FSE) imaging
Number of subjects: 0
Study 7767691 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial memory training (encoding operations, attentional functions, relaxation)
Number of subjects: 46
Study 7767691 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial memory training
Number of subjects: 46
Study 7767691 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 2216613 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nebulized albuterol (0.30 mg/kg body weight)
Number of subjects: 33
Study 2216613 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose nebulized albuterol (0.15 mg/kg body weight)
Number of subjects: 33
Study 369923 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldactone 100 mg daily
Number of subjects: 21
Study 369923 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol and Aldactone 200 mg daily
Number of subjects: 21
Study 369923 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Aldactone and acebutolol
Number of subjects: 21
Study 29061739 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg/day, n=17)
Number of subjects: 33
Study 29061739 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg/day, n=16)
Number of subjects: 33
Study 27355500 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding buddy program
Number of subjects: 625
Study 27355500 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 625
Study 22357166 — intervention group
Group type: EXPERIMENTAL
Intervention: IRO-A (15 mg)
Number of subjects: 40
Study 22357166 — intervention group
Group type: EXPERIMENTAL
Intervention: IRO-A with niacin (60 mg)
Number of subjects: 40
Study 22357166 — intervention group
Group type: COMPARATOR
Intervention: Roxicodone (IRO) (15 mg)
Number of subjects: 40
Study 23288372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 4503
Study 23288372 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 4503
Study 20426584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasted acid-etched surface
Number of subjects: 7
Study 20426584 — intervention group
Group type: COMPARATOR
Intervention: Machined surface
Number of subjects: 7
Study 18534246 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 58
Study 18534246 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 58
Study 15810797 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified milk (15 mg of iron per day per 400 ml)
Number of subjects: 168
Study 15810797 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements (60 mg of iron per day)
Number of subjects: 168
Study 15810797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 15810797 — intervention group
Group type: COMPARATOR
Intervention: Nonfortified milk
Number of subjects: 168
Study 11991533 — intervention group
Group type: EXPERIMENTAL
Intervention: Homogeneous enzyme immunoassay (EIA) for cotinine in urine
Number of subjects: 218
Study 11991533 — intervention group
Group type: COMPARATOR
Intervention: Breath carbon monoxide measurement
Number of subjects: 218
Study 10082055 — intervention group
Group type: EXPERIMENTAL
Intervention: Paremyd (0.25% tropicamide and 1.0% hydroxyamphetamine hydrobromide)
Number of subjects: 0
Study 10082055 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapiprazole (Rev‐Eyes)
Number of subjects: 0
Study 10082055 — intervention group
Group type: EXPERIMENTAL
Intervention: Paremyd with Dapiprazole
Number of subjects: 0
Study 10082055 — intervention group
Group type: COMPARATOR
Intervention: Control (no dapiprazole)
Number of subjects: 0
Study 10082055 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapiprazole
Number of subjects: 0
Study 8534463 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine plus scopolamine 0.25 mg via epidural catheter
Number of subjects: 50
Study 8534463 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone 2.5 to 4 mg via epidural catheter
Number of subjects: 50
Study 2324256 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (daily monitoring from the 6th day of stimulation)
Number of subjects: 108
Study 2324256 — intervention group
Group type: COMPARATOR
Intervention: Group B (monitoring from the 11th day of stimulation)
Number of subjects: 108
Study 7351723 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g cinoxacin at bedtime for 6 months
Number of subjects: 70
Study 7351723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 31146717 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 plus placebo
Number of subjects: 0
Study 31146717 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 plus pertuzumab
Number of subjects: 0
Study 31146717 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab plus taxane
Number of subjects: 0
Study 31146717 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 0
Study 31146717 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 (with or without pertuzumab)
Number of subjects: 0
Study 31146717 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 mRNA expression and mutated PIK3CA
Number of subjects: 0
Study 28445315 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% eye drops for 3 months
Number of subjects: 62
Study 28445315 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (control)
Number of subjects: 62
Study 26268408 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Number of subjects: 229
Study 23381297 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once daily for 5 days
Number of subjects: 148
Study 23381297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 21822151 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipedicular kyphoplasty (KP)
Number of subjects: 50
Study 21822151 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipedicular kyphoplasty (KP)
Number of subjects: 50
Study 19407810 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Wise Program (WWP)
Number of subjects: 143
Study 19407810 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 143
Study 16972915 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis educational programme
Number of subjects: 128
Study 16972915 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study 14593367 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) infused intravenously for 54.2±22.3 hours
Number of subjects: 18
Study 14593367 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) enoxaparin 1 mg/kg b.i.d. subcutaneously for 76.2±28.3 hours
Number of subjects: 18
Study 14593367 — intervention group
Group type: COMPARATOR
Intervention: Control group from randomized studies of thienopyridines in NSTEACS
Number of subjects: 18
Study 11192133 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin extended-release (two 500-mg tablets once daily for 7 days)
Number of subjects: 620
Study 11192133 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin immediate-release (one 500-mg tablet twice daily for 7 days)
Number of subjects: 620
Study 11192133 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin extended-release
Number of subjects: 620
Study 11192133 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin immediate-release
Number of subjects: 620
Study 9170464 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor (group I)
Number of subjects: 273
Study 9170464 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (group II)
Number of subjects: 273
Study 8251280 — intervention group
Group type: EXPERIMENTAL
Intervention: tropisetron 5 mg
Number of subjects: 54
Study 8251280 — intervention group
Group type: COMPARATOR
Intervention: saline 5 ml (control)
Number of subjects: 54
Study 3927342 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital; specific doses not mentioned
Number of subjects: 0
Study 3927342 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbital; specific doses not mentioned
Number of subjects: 0
Study 3927342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol; specific doses not mentioned
Number of subjects: 0
Study 30531305 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Vitamin D3 (1000 IU)
Number of subjects: 85
Study 30531305 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose Vitamin D3 (3000 IU)
Number of subjects: 85
Study 30531305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 30246286 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg/d
Number of subjects: 78
Study 30246286 — intervention group
Group type: COMPARATOR
Intervention: Control (increased hypoglycemic dosage/addition of another hypoglycemic agent)
Number of subjects: 78
Study 27364043 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.05 mg to 0.2 mg daily)
Number of subjects: 210
Study 27364043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 24862297 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT)
Number of subjects: 18
Study 24862297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 24862297 — intervention group
Group type: EXPERIMENTAL
Intervention: Early life stress (ELS)
Number of subjects: 18
Study 22569349 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk (540 g)
Number of subjects: 6
Study 22569349 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt (540 g)
Number of subjects: 6
Study 22569349 — intervention group
Group type: COMPARATOR
Intervention: Milk
Number of subjects: 6
Study 20425222 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal neuroimaging (CT or MRI)
Number of subjects: 0
Study 20425222 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute and long-term treatment decisions based on neuroimaging results
Number of subjects: 0
Study 18622778 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) group treatment for 10 weeks
Number of subjects: 347
Study 18622778 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 347
Study 16080635 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Carbohydrates (LC) diet
Number of subjects: 71
Study 16080635 — intervention group
Group type: COMPARATOR
Intervention: Low Fat (LF) diet
Number of subjects: 71
Study 11981149 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension induced by sodium nitroprusside and hyperoxic ventilation (CH-100%; n = 14)
Number of subjects: 42
Study 11981149 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypotension and ventilation with 50% O2 in nitrous oxide (CH-50%; n = 14)
Number of subjects: 42
Study 11981149 — intervention group
Group type: COMPARATOR
Intervention: Standard normotensive anesthesia with 50% O2 in nitrous oxide (control; n = 14)
Number of subjects: 42
Study 10969685 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (140 microg x kg(‐1) x min(‐1) for 5 minutes)
Number of subjects: 45
Study 10969685 — intervention group
Group type: COMPARATOR
Intervention: Control (15 minutes of prearrest drug-free bypass)
Number of subjects: 45
Study 10969685 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 45
Study 10969685 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 8794036 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine A (target trough levels 200 to 400 micrograms/L; group A; n = 15)
Number of subjects: 30
Study 8794036 — intervention group
Group type: COMPARATOR
Intervention: Usual cyclosporine dosage (target levels 400 to 600 micrograms/L; group B; n = 15)
Number of subjects: 30
Study 8794036 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine A (group A)
Number of subjects: 30
Study 8794036 — intervention group
Group type: COMPARATOR
Intervention: Usual cyclosporine dosage (group B)
Number of subjects: 30
Study 1583085 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet formulation of tetroxoprim (100 mg) and sulphadiazine (250 mg)
Number of subjects: 12
Study 1583085 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, assumed to be the other tablet formulation)
Number of subjects: 12
Study 6706043 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide
Number of subjects: 21
Study 6706043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31235400 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosehip seed oil (RHO) extract applied to 80 hands.
Number of subjects: 68
Study 31235400 — intervention group
Group type: COMPARATOR
Intervention: Control group (56 hands).
Number of subjects: 68
Study 30927953 — intervention group
Group type: EXPERIMENTAL
Intervention: Model A + B (histogram analysis combined with morphological characteristics)
Number of subjects: 289
Study 30927953 — intervention group
Group type: EXPERIMENTAL
Intervention: Model A + B
Number of subjects: 289
Study 30927953 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropy, microvascular sign, maximum diameter (independent predictors in IAC group)
Number of subjects: 289
Study 28375708 — intervention group
Group type: EXPERIMENTAL
Intervention: 22,600-ppm fluoride varnish, toothbrush, 50-mL tube of 1,450 ppm fluoride toothpaste, and standardized, evidence-based prevention advice
Number of subjects: 1248
Study 28375708 — intervention group
Group type: COMPARATOR
Intervention: Advice-only control
Number of subjects: 1248
Study 28375708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1248
Study 28375708 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1248
Study 25966108 — intervention group
Group type: EXPERIMENTAL
Intervention: tiaomian III decoction
Number of subjects: 61
Study 25966108 — intervention group
Group type: COMPARATOR
Intervention: active immunotherapy with paternal lymphocytes (Control)
Number of subjects: 61
Study 23689739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 μg) plus oxytocin infusion (20 IU)
Number of subjects: 380
Study 23689739 — intervention group
Group type: COMPARATOR
Intervention: Intravenous carbetocin (100 μg)
Number of subjects: 380
Study 23689739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol plus oxytocin infusion
Number of subjects: 380
Study 20974289 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention based on the Diabetes Prevention Program (DPP)
Number of subjects: 301
Study 20974289 — intervention group
Group type: COMPARATOR
Intervention: Mass mailing recruitment strategy
Number of subjects: 301
Study 20974289 — intervention group
Group type: COMPARATOR
Intervention: Mass mailing effectiveness
Number of subjects: 301
Study 20974289 — intervention group
Group type: COMPARATOR
Intervention: Recruitment cost
Number of subjects: 301
Study 17999781 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years group parenting programme combined with a new programme designed to train parents to support their children's reading at home
Number of subjects: 104
Study 16424345 — intervention group
Group type: COMPARATOR
Intervention: rs2227631 A allele in nonsmokers
Number of subjects: 1853
Study 16424345 — intervention group
Group type: COMPARATOR
Intervention: rs1799889 4G allele in nonsmokers
Number of subjects: 1853
Study 16424345 — intervention group
Group type: COMPARATOR
Intervention: Haplotype A-4G-A-A-C in nonsmokers
Number of subjects: 1853
Study 12568631 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide 300 mg/day
Number of subjects: 35
Study 12568631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 11152783 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided pneumatic reduction at 60 mm Hg for 30 seconds
Number of subjects: 49
Study 11152783 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided pneumatic reduction at 120 mm Hg (for unreducible cases)
Number of subjects: 49
Study 11152783 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided pneumatic reduction
Number of subjects: 49
Study 9244026 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Macintosh blade
Number of subjects: 46
Study 9244026 — intervention group
Group type: COMPARATOR
Intervention: Standard Macintosh blade
Number of subjects: 46
Study 8387421 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest computed tomographic (CT) scan
Number of subjects: 103
Study 8387421 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic bronchoscopy (FOB)
Number of subjects: 103
Study 8387421 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FOB and CT scan
Number of subjects: 103
Study 8387421 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 103
Study 8387421 — intervention group
Group type: EXPERIMENTAL
Intervention: FOB
Number of subjects: 103
Study 2880530 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 40
Study 2880530 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose in water (D5W)
Number of subjects: 40
Study 2675812 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 24
Study 2675812 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine
Number of subjects: 24
Study 2675812 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cholestyramine and simvastatin
Number of subjects: 24
Study 29190851 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (N=15) performed 60-min supervised treadmill exercise at moderate intensity (70% of HRmax) for 3 days per week for 4 weeks
Number of subjects: 27
Study 29190851 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=12) did not exercise
Number of subjects: 27
Study 28881182 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical staples
Number of subjects: 124
Study 28881182 — intervention group
Group type: COMPARATOR
Intervention: Nonabsorbable monofilament sutures
Number of subjects: 124
Study 23635890 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel piercings
Number of subjects: 80
Study 23635890 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene piercings
Number of subjects: 80
Study 23635890 — intervention group
Group type: COMPARATOR
Intervention: Polytetrafluoroethylene piercings
Number of subjects: 80
Study 23635890 — intervention group
Group type: COMPARATOR
Intervention: Other materials
Number of subjects: 80